Buyer's Market

Current employment options favor companies as well as less-experienced workers.

Written byBetsy Alberty
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The biotech industry has yet to recover fully from the boom and then bust of 2000-2001. Venture investment in biotech was $4.34 billion in 2000 but then dropped off for several years. Overall, it has started to pick up again, registering $4.18 billion in 2004 and $3.77 billion in 2005, according to a recent PricewaterhouseCoopers MoneyTree survey. Investment in the medical-device sector has also recently seen a reversal of a downward trend ($2.50 billion invested in 2000 followed by a drop, and rising again since 2004, registering $2.15 billion in 2005). Hiring follows investments by 6-12 months, however, and as a recruiter, I did not see a significant increase in hiring activity until late 2004-2005, when hiring focused on the growing areas of clinical and regulatory positions. Overall, hiring is still a buyer's (i.e., company's) market.

One result is a steadily increasing pool of highly experienced candidates who are being ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Explore new strategies for improving plasmid DNA manufacturing workflows.

Overcoming Obstacles in Plasmid DNA Manufacturing

cytiva logo

Products

The Scientist Placeholder Image

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

agilent-logo

Agilent Announces the Enhanced 8850 Gas Chromatograph

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies